SCHEMBL6473080

SCHEMBL6473080

CCCCCCC(=O)N(C)Cc1cccc(-c2ccc(C=C(CC(=O)OCC)C(=O)OC)cc2)c1

nearest known ligand 0.47

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 16/20 0.41
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6473078 0.94 AOC3 (0.41) AOC3BCHEACHE
SCHEMBL4227730 0.88 AOC3 (0.43) AOC3
SCHEMBL4227727 0.85 AOC3 (0.44) AOC3
SCHEMBL4227729 0.85 AOC3 (0.44) AOC3
SCHEMBL6182810 0.84 AOC3 (0.47) AOC3
SCHEMBL4209444 0.83 AOC3 (0.47) AOC3
SCHEMBL4209438 0.83 AOC3 (0.47) AOC3
SCHEMBL4209450 0.83 AOC3 (0.47) AOC3
SCHEMBL6473073 0.83 EPHX2 (0.38)
SCHEMBL6473082 0.83 EPHX2 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6927228-B2 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-09 US disclosed
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors PPARG, PPARA, PPARD AOC3 1747/4885BCHE 1768/4885ACHE 3608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.